ID3
Gene Information
- Official Symbol: ID3
- Official Name: inhibitor of DNA binding 3, HLH protein
- Aliases and Previous Symbols: N/A
- Entrez ID: 3399
- UniProt: Q02535
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: Open OMIM
Function Summary
- Entrez Summary: N/A
- UniProt Summary: Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Involved in myogenesis by inhibiting skeletal muscle and cardiac myocyte differentiation and promoting muscle precursor cells proliferation. Inhibits the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer. {ECO:0000269|PubMed:8437843}.
Pfam Domains GO Terms
Pfam Domains
| HLH |
GO Terms
| leptomycin B binding |
| response to leptomycin B |
| cellular response to leptomycin B |
| notochord development |
| negative regulation of myoblast differentiation |
| negative regulation of osteoblast differentiation |
| regulation of myoblast differentiation |
| negative regulation of DNA binding |
| cellular response to fatty acid |
| RNA polymerase II transcription factor binding |
| negative regulation of ossification |
| metanephros development |
| response to fatty acid |
| regulation of DNA replication |
| regulation of osteoblast differentiation |
| cellular response to antibiotic |
| odontogenesis |
| regulation of DNA binding |
| circadian rhythm |
| protein dimerization activity |
| negative regulation of DNA-binding transcription factor activity |
| negative regulation of binding |
| regulation of ossification |
| cellular response to acid chemical |
| negative regulation of neuron differentiation |
| transcription corepressor activity |
| protein domain specific binding |
| kidney development |
| rhythmic process |
| renal system development |
| negative regulation of neurogenesis |
| muscle organ development |
| response to antibiotic |
| negative regulation of nervous system development |
| urogenital system development |
| transcription factor binding |
| negative regulation of cell development |
| response to acid chemical |
| regulation of binding |
| regulation of DNA-binding transcription factor activity |
| embryonic organ development |
| muscle structure development |
| cellular response to lipid |
| heart development |
| cellular response to organic cyclic compound |
| response to wounding |
| transcription, DNA-templated |
| nucleic acid-templated transcription |
| positive regulation of apoptotic process |
| positive regulation of programmed cell death |
| RNA biosynthetic process |
| regulation of neuron differentiation |
| DNA-binding transcription factor activity |
| epithelial cell differentiation |
| positive regulation of cell death |
| negative regulation of cell differentiation |
| regulation of neurogenesis |
| response to lipid |
| negative regulation of transcription by RNA polymerase II |
| circulatory system development |
| response to organic cyclic compound |
| regulation of nervous system development |
| regulation of cell development |
| negative regulation of developmental process |
| animal organ morphogenesis |
| embryo development |
| central nervous system development |
| neuron differentiation |
| cellular response to oxygen-containing compound |
| nucleobase-containing compound biosynthetic process |
| epithelium development |
| negative regulation of molecular function |
| heterocycle biosynthetic process |
| aromatic compound biosynthetic process |
| regulation of cell cycle |
| negative regulation of transcription, DNA-templated |
| negative regulation of multicellular organismal process |
| negative regulation of nucleic acid-templated transcription |
| negative regulation of RNA biosynthetic process |
| organic cyclic compound biosynthetic process |
| negative regulation of RNA metabolic process |
| negative regulation of cellular macromolecule biosynthetic process |
| negative regulation of nucleobase-containing compound metabolic process |
| negative regulation of macromolecule biosynthetic process |
| negative regulation of cellular biosynthetic process |
| generation of neurons |
| regulation of apoptotic process |
| negative regulation of biosynthetic process |
| response to oxygen-containing compound |
| DNA-binding transcription factor activity, RNA polymerase II-specific |
| regulation of programmed cell death |
| neurogenesis |
| cellular nitrogen compound biosynthetic process |
| RNA metabolic process |
| regulation of cell death |
| cellular macromolecule biosynthetic process |
| negative regulation of gene expression |
| tissue development |
| macromolecule biosynthetic process |
| regulation of cell differentiation |
| gene expression |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
Most Correlated Genes in Chemogenomics
| Gene | Correlation |
|---|---|
| NSD1 | 0.756 |
| BAP1 | 0.672 |
| DOHH | 0.621 |
| RPTOR | 0.606 |
| TRIM28 | 0.602 |
| CCDC101 | 0.601 |
| CBFB | 0.598 |
| RUNX1 | 0.595 |
| ZNF592 | 0.573 |
| ASXL2 | 0.563 |
| TLE4 | 0.562 |
| BRPF1 | 0.557 |
| TRIM33 | 0.555 |
| WDR24 | 0.555 |
| MTOR | 0.547 |
| USP22 | 0.542 |
| SSBP2 | 0.541 |
| MAML1 | 0.54 |
| IRF2BP2 | 0.539 |
| ZMYM2 | 0.527 |
| MLST8 | 0.521 |
| ZFX | 0.516 |
| ATF7IP | 0.51 |
| LDB1 | 0.504 |
| SETDB1 | 0.504 |
| ID4 | 0.501 |
| UBE2G2 | 0.497 |
| MED23 | 0.494 |
| XPO6 | 0.491 |
| LMO2 | 0.491 |
| SCAF8 | 0.488 |
| CBX3 | 0.488 |
| DDX5 | 0.484 |
| FBXO11 | 0.484 |
| OTUD5 | 0.483 |
| GLTSCR1L | 0.481 |
| SOX7 | 0.476 |
| IRF2BP1 | 0.476 |
| TAF5L | 0.473 |
| PPP2R3C | 0.472 |
| VHL | 0.468 |
| ASB7 | 0.461 |
| AARS | 0.454 |
| FAF2 | 0.454 |
| TRIP12 | 0.452 |
| AGO2 | 0.45 |
| HHEX | 0.449 |
| DCAF5 | 0.448 |
| ENY2 | 0.446 |
| SUPT7L | 0.445 |
| UBE2L3 | 0.444 |
| TMEM41B | 0.443 |
| TP53 | 0.443 |
| CELF1 | 0.439 |
| ARL14EP | 0.439 |
| MEF2C | 0.438 |
| ACTB | 0.438 |
| HELZ | 0.435 |
| ZMIZ1 | 0.435 |
| TADA2B | 0.435 |
| LAMTOR4 | 0.434 |
| BRD9 | 0.433 |
| ZNF608 | 0.432 |
| MLLT1 | 0.429 |
| RNMT | 0.429 |
| OPA1 | 0.425 |
| HARS | 0.422 |
| BPTF | 0.42 |
| HCCS | 0.416 |
| THG1L | 0.416 |
| WDR59 | 0.416 |
| UBE2K | 0.416 |
| ZBTB44 | 0.415 |
| DPAGT1 | 0.412 |
| SSB | 0.411 |
| SEC63 | 0.411 |
| TRMT10A | 0.411 |
| MIOS | 0.411 |
| GMPPB | 0.409 |
| SERF2 | 0.409 |
| LSM11 | 0.409 |
| ERG | 0.408 |
| DR1 | 0.408 |
| LYL1 | 0.407 |
| MED25 | 0.407 |
| MEAF6 | 0.407 |
| UAP1 | 0.406 |
| KDM6B | 0.406 |
| EGLN1 | 0.404 |
| TADA3 | 0.402 |
| DNAJC3 | 0.401 |
| BAK1 | 0.401 |
| SP3 | 0.4 |
| TTI1 | 0.4 |
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 0/726
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 0/1 |
| 909776.0 | 0/1 |
| bile duct | 0/28 |
| blood | 0/28 |
| bone | 0/25 |
| breast | 0/33 |
| central nervous system | 0/56 |
| cervix | 0/4 |
| colorectal | 0/17 |
| esophagus | 0/13 |
| fibroblast | 0/1 |
| gastric | 0/15 |
| kidney | 0/21 |
| liver | 0/20 |
| lung | 0/75 |
| lymphocyte | 0/14 |
| ovary | 0/26 |
| pancreas | 0/24 |
| peripheral nervous system | 0/16 |
| plasma cell | 0/15 |
| prostate | 0/1 |
| skin | 0/24 |
| soft tissue | 0/7 |
| thyroid | 0/2 |
| upper aerodigestive | 0/22 |
| urinary tract | 0/29 |
| uterus | 0/5 |
Essentiality in NALM6
- Essentiality Rank: 1498
- Expression level (log2 read counts): 5.99
Expression Distribution
ID3 Expression in NALM6 Cells: 5.99
